| 000 | 01811 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514162109.0 | ||
| 264 | 0 | _c20031202 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a0004-3591 | ||
| 024 | 7 |
_a10.1002/art.11304 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCostedoat-Chalumeau, Nathalie | |
| 245 | 0 | 0 |
_aSafety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. _h[electronic resource] |
| 260 |
_bArthritis and rheumatism _cNov 2003 |
||
| 300 |
_a3207-11 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xpharmacokinetics |
| 650 | 0 | 4 |
_aBirth Weight _xdrug effects |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxychloroquine _xpharmacokinetics |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xcomplications |
| 650 | 0 | 4 | _aMaternal Age |
| 650 | 0 | 4 | _aMaternal Exposure |
| 650 | 0 | 4 | _aMaternal-Fetal Exchange |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 | _aPregnancy Complications |
| 650 | 0 | 4 | _aPregnancy Outcome |
| 650 | 0 | 4 | _aPregnancy, High-Risk |
| 650 | 0 | 4 | _aPrenatal Exposure Delayed Effects |
| 700 | 1 | _aAmoura, Zahir | |
| 700 | 1 | _aDuhaut, Pierre | |
| 700 | 1 | _aHuong, Du Le Thi | |
| 700 | 1 | _aSebbough, Djamel | |
| 700 | 1 | _aWechsler, Bertrand | |
| 700 | 1 | _aVauthier, Danièle | |
| 700 | 1 | _aDenjoy, Isabelle | |
| 700 | 1 | _aLupoglazoff, Jean-Marc | |
| 700 | 1 | _aPiette, Jean-Charles | |
| 773 | 0 |
_tArthritis and rheumatism _gvol. 48 _gno. 11 _gp. 3207-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/art.11304 _zAvailable from publisher's website |
| 999 |
_c14350524 _d14350524 |
||